

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 in pregnancy, adapting vaccines in the changing face of SARS-CoV-2, Evusheld for preventing COVID-19 during Omicron

Peer reviewed journals featured:

- An update to a BMJ living systematic review on COVID-19 in pregnancy [here](#)
- Systematic reviews on:
 - The effectiveness of heterologous and homologous COVID-19 vaccine regimens [here](#)
 - COVID-19 vaccines for people with haematological malignancies [here](#)
 - Acute and post-acute COVID-19 presentations in athletes [here](#) and associated editorial [here](#)
- A narrative review on rapid isolation and characterisation of SARS-CoV-2 variants in Australia [here](#)
- Observational studies on:
 - Analysing and modelling the spread of Omicron lineages BA.1 and BA.2 in France [here](#)
 - SARS-CoV-2 antibody titres associated with clinical outcomes in severe COVID-19 [here](#)
 - Clinical characteristics and social determinants of health associated with 30-day hospital readmissions of COVID-19 patients [here](#)
 - A modelling study on reconstructing SARS-CoV-2 transmission dynamics using excess mortality data [here](#)
 - SARS-CoV-2 related serological signatures in children [here](#)
 - Anticipatory prescribing in community-based end-of-life care during COVID-19 [here](#)
 - Cross-neutralisation of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2 [here](#)
- An editorial on long term implications of COVID-19 in pregnancy [here](#)
- Commentary on:
 - Adapting vaccines to the changing face of SARS-CoV-2 [here](#)
 - COVID-19 in 2022 – the beginning of the end or the end of the beginning? [here](#)
 - Prognostic modelling and dataset shifts during COVID-19 [here](#)
 - An early warning system for emerging SARS-CoV-2 variants [here](#)
 - Adrenal function in patients with long COVID [here](#)
 - The black market for COVID-19 antiviral drugs [here](#)
 - Vaccine mandates for healthcare workers [here](#)

Pre-peer review articles featured:

- Tixagevimab/cilgavimab (Evusheld) for preventing COVID-19 during the Omicron surge [here](#)
- A third interim analysis of a living systematic review on COVID-19 vaccine effectiveness against Omicron [here](#)
- Cognitive dysfunction in COVID-19 [here](#)
- Protection against Omicron conferred by mRNA vaccination and prior infection [here](#)
- Epidemiological interactions of influenza and SARS-CoV-2 within a US university during Omicron B.1.1.529 outbreak [here](#)
- Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolution and antibody evasion [here](#)
- Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir during the Omicron BA.2.2 wave in Hong Kong [here](#)
- The prevalence of SARS-CoV-2 infection and uptake of COVID-19 antiviral treatments during the Omicron BA.2/BA.2.12.1 surge in New York City [here](#)

Guidance and reports

- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)

News and blogs

- COVID-19 'rebound' [here](#)
- Case rises in the Americas driven by increases in North and Central America [here](#)
- A podcast on COVID-19's devastating impact on lost education [here](#)
- Why call it BA.2.12.1? A guide to the tangled Omicron family [here](#)
- Care of patients with new, continuing, or recurring symptoms after acute SARS-CoV-2 infection [here](#)
- Two million people in the UK are estimated to be experiencing long COVID [here](#)
- Scientists acknowledge errors in the WHO COVID-19 mortality estimates [here](#)

[Click here](#) to subscribe to the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).